Evaluation of Pegylated Liposomal Doxorubicin in the Treatment Of Both Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer
Objective: Pegylated liposomal doxorubicin (PLD) is a stealth liposomal form of doxorubicin that has been approved for the treatment of patients with relapsed ovarian cancer. Previous studies have shown a response rate of about 25% in patients who had treatment failure with prior platinum- and/or pa...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2004-09-01
|
| Col·lecció: | Taiwanese Journal of Obstetrics & Gynecology |
| Matèries: | |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S1028455909600711 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|